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Myotonic dystrophy type 1 is the most common form of muscular dystrophy in adults,
and is primarily characterized by muscle weakness and myotonia, yet some of the most
disabling symptoms of the disease are cognitive and behavioral. Here we evaluated
several of these non-motor symptoms from a cross-sectional time-point in one of the
largest longitudinal studies to date, including full-scale intelligence quotient, depression,
anxiety, apathy, sleep, and cerebral white matter fractional anisotropy in a group of
39 adult-onset myotonic dystrophy type 1 participants (27 female) compared to 79
unaffected control participants (46 female). We show that intelligence quotient was
significantly associated with depression (P < 0.0001) and anxiety (P = 0.018), but
not apathy (P < 0.058) or hypersomnolence (P = 0.266) in the DM1 group. When
controlling for intelligence quotient, cerebral white matter fractional anisotropy was
significantly associated with apathy (P = 0.042) and hypersomnolence (P = 0.034),
but not depression (P = 0.679) or anxiety (P = 0.731) in the myotonic dystrophy
type 1 group. Finally, we found that disease duration was significantly associated with
apathy (P < 0.0001), hypersomnolence (P < 0.001), IQ (P = 0.038), and cerebral white
matter fractional anisotropy (P < 0.001), but not depression (P = 0.271) or anxiety
(P= 0.508). Our results support the hypothesis that cognitive deficits, hypersomnolence,
and apathy, are due to the underlying neuropathology of myotonic dystrophy type
1, as measured by cerebral white matter fractional anisotropy and disease duration.
Whereas elevated symptoms of depression and anxiety in myotonic dystrophy type 1 are
secondary to the physical symptoms and the emotional stress of coping with a chronic
and debilitating disease. Results from this work contribute to a better understanding of
disease neuropathology and represent important therapeutic targets for clinical trials.
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INTRODUCTION
Myotonic dystrophy type 1 (DM1) is a trinucleotide repeat
disorder, classically characterized with motor symptoms of
prolonged muscle contractions (myotonia), progressive muscle
wasting, and weakness (1). As a multisystemic disease, DM1
manifests with many additional non-motor symptoms including
cataracts, heart conduction abnormalities and arrythmias,
gastrointestinal abnormalities, endocrine abnormalities, insulin
resistance and diabetes, and respiratory failure. Other non-
motor symptoms, including cognitive deficits, sleep disturbances
and affective symptoms, are thought to be due to CNS
pathology in DM1, a feature of the disease that has had
increasing focus over the past 5–10 years. White matter
(WM) microstructure pathology is one of the most robust
and reproducible observations in DM1, supported by several
neuroimaging studies to date (2–13). Fractional Anisotropy (FA,
obtained via diffusion tensor MR imaging [DTI]) provides a
measure of WM microstructural integrity by quantifying local
restrictions of the direction of diffusion of water molecules and
ranges from 0 (e.g., cerebrospinal fluid) to ∼1 (e.g., highly
myelinated WM fiber bundles). In DM1, FA has been shown to
be globally reduced, with limited regional specificity (3–14).
As a single gene disorder, there has been significant progress
toward developing gene knock-down or other therapies directed
at the core site of pathology in DM1. To treat the CNS associated
symptoms of DM1, there is consideration and progress toward
delivery of these therapies directly to the brain (15). In the context
of developing endpoints for monitoring centrally administered
therapy, it is crucial to distinguish what features of DM1 are truly
related to brain pathology and which features may be secondary
manifestations of living with a chronic neurologic disease.
This will move the field toward more robust clinical targets,
biomarkers, and endpoints for clinical trials. The symptoms
of DM1 considered directly related to brain pathology include
cognitive deficits, apathy, hypersomnolence/fatigue, and affective
symptoms of depression and anxiety (15). These symptoms
can have a significant burden on both the patient and their
caregiver (15–17).
It is important to consider the potential relationships between
the symptoms of DM1 when evaluating whether or not they
represent core features of the disease. General cognitive deficits
are severe in congenital and childhood forms of DM1 (18),
but even in adult-onset DM1, we have shown that Full Scale
IQ (FSIQ) is significantly lower than unaffected healthy adults
(19, 20). Although verbal skills are typically less affected
than visuospatial skills, a significantly lower FSIQ highlights a
generalized deficit in cognitive skills. There is also significant
evidence for global cognitive deficits in adult-onset DM1 present
across several different domains (21). For patients navigating
Abbreviations: AES, apathy evaluation scale; BDI-II, beck depression inventory-
II; BDA, beck anxiety inventory; DM1, myotonic dystrophy type 1; DTI, diffusion
tensor imaging; EEG, electroencephalography; ePAL, estimated progenitor allele
length; FA, fractional anisotropy; MRI, magnetic resonance imaging; FSIQ, full
scale intelligence quotient; SCOPA, scales for outcomes in Parkinson’s disease; SP-
PCR, small-pool polymerase chain reaction; WAIS-IV, Wechsler adult intelligence
scale-IV; WM, white matter.
the burden of having a degenerative neurologic disorder, deficits
in cognitive skills can result in sub-optimal coping strategies
potentially driving secondary emotional problems, including
depression and anxiety.
The majority of studies evaluating depression in DM1 have
utilized rating scales such as the Beck Depression Inventory
(BDI) (6, 9, 10, 14, 16, 22–28), the Hamilton Rating Scale for
Depression (HAM-D) (29–34) or a variety of other standardized,
self-rating scales (35–48), and comparison groups were often
adults with no major medical illnesses. However, rating scales
such as the BDI-II not only assess mood and cognitive
symptoms such as sadness, suicidality, and guilt, but also
somatic symptoms such as fatigue and sleep disturbance. When
using depression rating scales, it is vital to determine whether
the scores are increased due to higher somatic ratings or
because of depressed mood, as many of the other symptoms of
DM1 (hypersomnolence, fatigue) will contribute to the overall
depression score.
To better understand whether these symptoms in DM1 are
truly related to brain pathology, a few studies have evaluated the
relationship between cerebral WM FA and symptoms. Several
studies have shown a relationship between lower FA, lower
cognitive function (9), and hypersomnolence (4). Yet, no study
has systematically evaluated all of these brain symptommeasures
together, while accounting for relationships among measures. In
addition, if a symptom of a progressive, worsening disease is truly
related to the pathology of that disease, that symptom would
worsen over the course of time. Therefore, the association of a
symptom with disease duration would also support the notion
that that symptom was due to progressive brain pathology, as
shown previously with cognitive performance (49, 50).
The Iowa DM1 study evaluates brain structure and function in
adult-onset DM1. Here, as part of this larger study, we evaluate
measures of cognitive/behavioral symptoms, including FSIQ,
depression, anxiety, apathy (obtained from both the participant
and an informant, as patients often under-rate this symptom),
and hypersomnolence. First, we evaluated the relationship
between cognitive impairment to ratings of depression, anxiety,
apathy, and hypersomnolence. Then, relationships between these
clinical measures and cerebral FAwere compared. Finally, disease
duration (as a marker of disease progression) was used as a
predictor for thesemeasures and cerebral FA. Our results indicate
that cognitive deficits, apathy, and hypersomnolence represent
that core brain symptoms of DM1.
PATIENTS AND METHODS
Participants
The Iowa DM1 Brain study targets individuals with adult-onset
DM1 (diagnosis after the age of 18 years old). Participants
were recruited from our multidisciplinary specialty clinic for
DM1 at the University of Iowa and through the Myotonic
Dystrophy Foundation. Healthy adults were recruited from
spouses of DM1 participants and from the Iowa City area via
advertisements. Exclusion criteria for all participants included:
MRI contraindication, a history of serious head injury that
resulted in a hospital stay, or a chronic neurological disorder
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TABLE 1 | Demographics of study sample.
Healthy controls DM1
Sample n 71 39
Sex n Males 25 12
Females 46 27
Age at evaluation Mean (SD) 43.22 (13.07) 45.49 (9.03)
Age at disease onset Mean (SD) n/a 32.35 (9.59)
Disease Duration Mean (SD) n/a 12.87 (7.38)
MIRS n MIRS 1 - 13
MIRS 2 - 24
MIRS 3 - 9
MIRS 4 - 4
MIRS 5 - 0
CTG Range 5–43 81–501
Median 13 146
other than DM1. Healthy adults were additionally required to be
without history of substance abuse, psychiatric disease, or major
medical disease, including heart disease, sleep disorder, vascular
disease, uncontrolled hypertension, cancer, diabetes mellitus,
lung disease, and autoimmune conditions. A total of 8 potential
DM1 participants and 9 potential healthy control participants
were either excluded or did not meet inclusion criteria for
the study and were excluded. The current sample included 39
individuals with DM1 and 71 healthy adults. Demographics are
displayed in Table 1. There was no significant difference in sex
(χ2 = 0.068, df = 1, p = 0.794) or age [t(108) = 0.96, p =
0.337] between groups. Disease duration was defined as the time
between onset of the first motor symptom of DM1 and time of
assessment. Mean disease duration for this group was 12.9 years
with a range of 2.4 years to 28.9 years. As far as the severity of
muscular impairment, the DM1 group had 13 individuals with a
score of one (no impairment), 24 with a score of two (minimal
signs), nine with a score of three (distal weakness), four with a
score of four (mild to moderate proximal weakness), and none
with a score of five (severe proximal weakness).
All participants gave written, informed consent prior to
enrolling in the protocol in accordance with the Declaration of
Helsinki. The study was approved by the University of Iowa
Institutional Review Board.
Genotyping of CTG repeat in DM1-affected participants was
completed by small-pool PCR (SP-PCR) (51). For each patient,
four reactions were completed, each using 300 pg genomic DNA
template derived from blood leukocytes. CTG repeat lengths
were estimated by comparison against DNA fragments of known
length and molecular weight markers, using CLIQS software
(TotalLabs UK Ltd.). The lower boundary of the expanded
molecules in SP-PCR was used to estimate the progenitor
(inherited) allele length (ePAL) (52). The mean ePAL for the
DM1 group was 146 with a minimum of 81 and a maximum of
501. Repeat lengths for the non-disease-causing alleles from all
participants were estimated using the Illumina MiSeq platform,
broadly as described for Huntington disease alleles (53). Primers
that flanked the CTG repeats were used to amplify across the
repeat region, also adding barcoded sequencing adapters to
generate the sequencing library. The resulting reads were aligned





sequences separated by 0–100 CTG repeats. The genotype was
the CTG repeat length to which the highest number of sequence
reads were mapped.
Research staff, clinicians, and scientists involved in this study
remained blind to the participant’s clinical condition (CTG
expansion length and muscular impairment). However, this was
not always possible when participants exhibited moderate-to-
severe symptoms of DM1 during the study. All clinical scales and
measures were administered by a trained examiner experienced
in DM1. All data were de-identified and all participants
consented to non-disclosure of genetic results obtained as part
of the study.
Motor Testing
Severity of muscle weakness was measured using the Muscle
Impairment Rating Scale (MIRS) during examination by a
neuromuscular specialist experienced in DM1, blinded to the
participants’ genetic status (54). This scale evaluates muscular
impairment severity according to an ordinal 5-point scale as
follows: (1) no muscular impairment, (2) minimal signs, (3)
distal weakness, (4) mild to moderate proximal weakness, and (5)
severe proximal weakness.
General Cognitive Abilities
Participants completed the Wechsler Adult Intelligence Scale-IV
(WAIS-IV) to estimate Full Scale IQ (55).
Depression and Anxiety
The Beck Depression Inventory (BDI-II) is a widely used
questionnaire measuring self-reported symptoms of depression
on a 4-point Likert scale ranging from 0 to 3 (56). A total score is
summed and can be interpreted clinically as 0–13 being minimal
depression; 14–19 being mild depression; 20–28 being moderate
depression; and 29–63 being severe depression. The Beck Anxiety
Inventory (BAI) is a corollary self-report questionnaire (21
questions on a 4-point Likert scale) assessing symptoms related
to anxiety.
Sleep Quality
The SCOPA-Sleep (Scales for Outcomes in Parkinson’s Disease-
Sleep) survey was used to assess daytime sleepiness (57). The
self-report scale includes six items in subscale D: Sleeping
during the day and evening, which were summed to calculate
hypersomnolence scores. Items used to measure overall sleep
quality from subscales A: Use of sleeping tablets, B: Sleeping at
night, and C: Global evaluation of sleeping at night, were not
included in the analysis.
Apathy
The Apathy Evaluation Scale (AES) was used to determine self-
reported degree of apathy (58). The AES includes 18 items that
are rated on a 4-point Likert scale. Items were summed to create
a total score, where higher scores represent increased apathy. In
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addition, we had a subset of 24 of the 39 participants with DM1
who had an informant fill out the informant version of the scale.
Magnetic Resonance Imaging
Individuals who participated before June 2016 (49 controls,
25 DM1) were scanned using a 3T Siemens TrioTIM scanner
(Siemens AG, Munich, Germany; 12 channel head coil, software
version: syngo B17). Those who participated after June 2016
were scanned using a 3T General Electric Discovery MR750w
scanner (GE Medical Systems, Chicago, Il, 16 channel head and
neck coil, software versions: 25.0, 25.1, and 26.0) (21 controls,
and 13 DM1). Participants completed DWI acquisitions with
either a single-shell (B1000, 64 directions), multi-shell (B1000
and B2000, 29-30 directions per shell), or both. Diffusion-
weighted images were collected using echo planar recovery
magnitude sequences collected in the axial plane. Anatomical
T1-weighted and T2-weighted images were collected and used
for co-registration, normalization, and labeling purposes using
acquisition parameters described previously (59).
Fractional Anisotropy
Diffusion-weighted images were processed using standard
procedures of the FMRIB Diffusion toolbox from the FSL
software package (http://www.fmrib.ox.ac.uk/fsl), where phase
encoding distortion and eddy current artifacts were removed
using topup and eddy tools respectively (60, 61). Following
correction, diffusion tensor models were generated using dtifit,
and from these tensors, scalar measures of anisotropy (FA) were
calculated. B0 maps were co-registered to T2-weighted image
for each participant, which were in turn registered to their T1-
weighted images, which were normalized to a standard space. All
registrations consisted of rigid, affine, and non-linear (symmetric
normalization) components andwere conducted using Advanced
Normalization Tools (62) and were applied together in a single
interpolation step to avoid compounding interpolation errors.
We focused on cerebral white matter FA for the current analysis,
rather than regional WM FA, given prior research indicating lack
of regional specificity of WM FA deficits in DM1.
Statistical Analyses
All statistical analyses were performed using R (version 3.6.2).
Linear regression models were run to compare group differences
across groups in depression, anxiety, apathy, sleep, FSIQ and
cerebral WM FA. All models were controlled for age, sex
and a sex-by-group interaction. The semi-partial coefficient of
determination (R2) for the model, and 95% confidence intervals
were calculated. Effect sizes were considered very small (R2 <
0.1), small (0.1 < R2 < 0.3), moderate (0.3 < R2 < 0.5), and
large (0.5 < R2) (63). The interaction term was removed from
the model if not significant at p < 0.05 and removed from
further analyses.
A second set of models determined the effect of FSIQ
(predictor variable) on the clinical measures of depression,
anxiety, apathy, and sleep (dependent variables).
Additionally, clinical outcome measures were modeled with
cerebral WM FA as the predictor variable. In order to account
for potential effects of FSIQ on the relationship between WM FA
and clinical outcomes, FSIQ was included if the coefficient was
statistically significant.
Finally, a set of models determined the effect of disease
duration (predictor variable) on the clinical measures of
depression, anxiety, apathy, sleep, and cerebral WM FA
(dependent variables).
RESULTS
Table 2 displays the comparison of the clinical measures and
cerebral WM FA across groups. As expected, patients with DM1
had significantly different clinical measures compared to healthy
adults. These results included lower FSIQ [t(106) = −6.16, P <
0.0001], and higher ratings of depression [t(106) = 8.12, P <
0.0001] and anxiety [t(106) = 5.29, P < 0.0001). Self-reported
apathy [t(106) = 5.86, P < 0.0001] and informant-reported
apathy scores [t(27) = 2.43, P = 0.0221] were also significantly
higher. Additionally, DM1 patients had higher daytime sleepiness
scores [t(106) = 8.41, P < 0.0001]. Finally, cerebral WM FA was
significantly lower in the DM1 group compared to healthy adults
[t(98) =−12.23, P < 0.0001].
BDI-II depression scores were subdivided into ranges, where
99% of healthy adults scored in the normal orminimal depression
range, and 1% in the mild depression range. For participants with
DM1, 72% were in the normal or minimal range, 18% were in the
mild range, 10% scored in the moderate range, and none scored
in the severe range.
Table 3 shows the results of the models that determined
associations between FSIQ and other clinical measures. FSIQ was
significantly associated with depression scores [t(35) = −3.60, P
< 0.001] and anxiety scores [t(35) = −2.47, P = 0.018], with
lower FSIQ associated with higher scores of both scales. However,
FSIQ was not associated with apathy (neither self-reported or
informant-reported scores) or daytime sleepiness.
Table 4 shows the results of the analyses evaluating
associations between cerebral WM FA and clinical measures.
Cerebral FA was strongly associated with FSIQ, where higher FA
was associated with higher FSIQ [t(29) = 3.61, P = 0.001]. FSIQ
was included in the models predicting depression and anxiety
with FA. There was no statistically significant relationship
between FA and depression [t(29) =−0.49, P = 0.679] or anxiety
[t(29) = 0.35, P = 0.731]. Cerebral FA was not associated with
apathy self-reported scores [t(29) = −1.88, P = 0.071], but
was significantly associated with apathy informant-reported
scores with small effect size [t(29) = ]2.20, P = 0.042]. Greater
white matter abnormality (lower FA) was associated with
higher informant-reported apathy scores. Finally, FA was also
significantly associated with hypersomnolence with small effect
size [t(29) = −2.22, P = 0.034], with greater white matter
abnormality being associated with higher sleepiness scores.
We found that disease duration (used as a measure of disease
progression) was significantly associated with cerebral FA [t(32)
=−4.28, P < 0.001] supporting the hypothesis that white matter
integrity decreases over time. Table 5 and Figure 1 shows the
results of the analysis evaluating associations between disease
duration with clinical measures and cerebral WM FA. We found
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TABLE 2 | Clinical outcome comparisons between groupsa.
Variable Estimate 95% CI t-value (df) P-value R2 R2 95% CI
FSIQ −14.83 (−19.60, −10.05) −6.13 (106) <0.0001 0.264 (0.139, 0.402)
Beck depression inventory 7.07 (5.35, 8.80) 8.12 (106) <0.0001 0.384 (0.255, 0.513)
Beck anxiety inventory 5.48 (3.43, 7.53) 5.29 (106) <0.0001 0.209 (0.093, 0.347)
AES: self-report 7.03 (4.65, 9.41) 5.86 (106) <0.0001 0.245 (0.122, 0.383)
AES: informant-report 10.32 (1.60, 19.04) 2.43 (106) 0.0221 0.225 (0.026, 0.504)
SCOPA: hypersomnolence 3.90 (2.98, 4.82) 8.41 (106) <0.0001 0.400 (0.271, 0.527)
Cerebral WM FA −0.05 (−0.05,−0.04) −12.23 (106) <0.0001 0.604 (0.497, 0.700)
aAll regression coefficients (estimate), 95% confidence intervals, t-values, P-values, and semi-partial R2 were calculated in the linear regression model, using group, age, and sex
as covariates.
AES, apathy evaluation scale; SCOPA, scales for outcomes in Parkinson’s disease; FSIQ, full scale intelligence quotient.
Bold values indicate they are significant at a p-value < 0.05.
TABLE 3 | FSIQ as a predictor of clinical outcomes in DM1a.
Variable β β 95% CI t-value (df) P-value R2 R2 95% CI
Beck depression inventory −0.50 (−0.78, −0.22) −3.60 (35) <0.001 0.270 (0.069, 0.510)
Beck anxiety inventory −0.38 (−0.70, −0.07) −2.47 (35) 0.018 0.149 (0.008, 0.392)
AES: self-report −0.28 (−0.58, 0.01) −1.96 (35) 0.058 0.099 (0.001, 0.332)
AES: informant-report 0.08 (−0.31, 0.46) 0.43 (21) 0.675 0.009 (0.000, 0.245)
SCOPA: hypersomnolence −0.18 (−0.51, 0.14) −1.13 (35) 0.266 0.035 (0.000, 0.232)
aAll standardized regression coefficients (β), 95% confidence intervals, t-values, P-values, and semi-partial R2 were calculated in the linear regression model, using group, age, and sex
as covariates.
AES, Apathy evaluation scale; SCOPA, scales for outcomes in Parkinson’s disease; FSIQ, full scale intelligence quotient.
Bold values indicate they are significant at a p-value < 0.05.
that disease duration (used as a marker for disease progression)
was significantly associated with apathy with a large effect size
[t(32) = 6.33, P < 0.0001]. Disease duration was also significantly
associated with hypersomnolence with moderate effect size [t(32)
= 3.69, P < 0.001]. Disease duration was not associated with
intelligence quotient [t(32) =−1.78, P = 0.085], depression [t(32)
= 1.12, P= 0.271], or anxiety [t(32) = 0.67, P= 0.508] (Figure 1).
DISCUSSION
Brain involvement in DM1 has increasingly become a focus of
attention over the past decade, in part because many of the
symptoms of DM1 that are attributable to the brain can be quite
distressing to patients and their families (43, 64, 65). However,
in the context of understanding the neurobiology of DM1 and
moving toward reliable therapeutic targets, it is vital to be able
to identify which symptoms are related to brain pathology and
which ones are secondary to the stress of dealing with a chronic
disease and not due to underlying brain pathology (15).
Previous studies have shown significant relationships between
neuroimaging findings and cognitive impairments, including
white matter track DTI measures, ventricular enlargement,
gray matter and white matter atrophy, white matter lesions,
increased hippocampal volume, and FDG-PET frontotemporal
hypometabolism (4, 9, 12, 19, 66–68). Previous studies have also
confirmed cognitive decline over time with age and a negative
association with disease duration (49, 50, 69, 70).
In support of the hypothesis that depression and anxiety
are not a manifestation of DM1 brain pathology, there was
no relationship to the primary brain imaging abnormality in
DM1 of decreased white matter FA. In addition, Hamilton et al.
(71) found no correlation between white matter lesion volume
(mL) and BDI-II scores and Winblad et al. (27) found that
white matter lesions may actually protect against depression. In
addition,Winblad et al. (27) found that depression was associated
with earlier stages of DM1 and was negatively correlated to
disease progression (27). The construct of depression as a clinical
disorder is predicated on a foundational principle of an altered
and depressed mood (i.e., feeling “sad”). A previous study by
Serra et al. (72) showed significant associations between cortical
thickness and social cognition performance, including sadness.
However, this study did not include any depression-specific scales
and had a relatively small sample size. In our current sample, the
DM1 patients, despite scoring high on other BDI-II items, did not
report feeling sad (Mean DM1 score on this itemwas 0.078, mean
healthy adult score was 0.028). Moreover, although individuals
with DM1 scored higher on the BDI-II, the healthy adult group
in our study was not the optimal comparison group. That is,
they were healthy and not suffering from a chronic, degenerative
medical condition. This suggests that the BDI-II is reflecting the
physical symptoms of DM1 rather than the emotional symptoms
that are more commonly associated with depression. This is
supported by the fact that there are no differences in the BDI-
II affective and somatic sub-domains in our study. Winblad et
al. (27) also found that DM1 patients tend to have high scores
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TABLE 4 | Cerebral white matter FA as a predictor of clinical outcomes in DM1a.
Variable β β 95% CI t-value (df) P-value R2 R2 95% CI
FSIQ 0.55 (0.24, 0.86) 3.61 (29) 0.001 0.309 (0.083, 0.566)
Beck Depression Inventory* −0.08 (−0.50, 0.33) −0.49 (29) 0.679 0.006 (0.000, 0.189)
Beck Anxiety Inventory* 0.07 (−0.36, 0.51) 0.35 (29) 0.731 0.004 (0.000, 0.183)
AES: self-report −0.30 (−0.64, 0.03) −1.88 (29) 0.071 0.108 (0.001, 0.370)
AES: informant-report −0.41 (−0.81, −0.02) −2.20 (19) 0.042 0.222 (0.006, 0.572)
SCOPA: hypersomnolence −0.37 (−0.71, −0.03) −2.22 (29) 0.034 0.145 (0.004, 0.414)
aAll standardized regression coefficients (β), 95% confidence intervals, t-values, P-values, and semi-partial R2 were calculated in the linear regression model, using group, age, and sex
as covariates.
AES, apathy evaluation scale; SCOPA, scales for outcomes in Parkinson’s disease; FSIQ, full scale intelligence quotient.
*FSIQ was entered into the model as a covariate.
Bold values indicate they are significant at a p-value < 0.05.
TABLE 5 | Disease duration as a predictor of clinical outcomes in DM1a.
Variable β β 95% CI t-value (df) P-value R2 R2 95% CI
FSIQ −0.31 (−0.67, 0.05) −1.78 (32) 0.085 0.090 (0.001, 0.332)
Beck depression inventory 0.19 (−0.16, 0.55) 1.12 (32) 0.271 0.038 (0.000, 0.153)
Beck anxiety inventory 0.12 (−0.24, 0.48) 0.67 (32) 0.508 0.014 (0.000, 0.251)
AES: self-report 0.37 (0.05, 0.69) 2.38 (32) 0.023 0.150 (0.010, 0.421)
AES: informant-report 0.72 (0.48, 0.96) 6.33 (19) <0.0001 0.678 (0.460, 0.843)
SCOPA: hypersomnolence 0.54 (0.24, 0.84) 3.692 (32) 0.0008 0.299 (0.083, 0.546)
Cerebral FA −0.68 (−1.00, −0.35) −4.277 (32) 0.0002 0.413 (0.162, 0.656)
aAll standardized regression coefficients (β), 95% confidence intervals, t-values, P-values, and semi-partial R2 were calculated in the linear regression model, using group, age, and sex
as covariates.
AES, apathy evaluation scale; SCOPA, scales for outcomes in Parkinson’s disease; FSIQ, full scale intelligence quotient.
Bold values indicate they are significant at a p-value < 0.05.
on somatic items and low scores on cognitive-affective items of
the BDI-II. In summary, these findings support the hypothesis
that what is likely being measured by the BDI-II (or other
standard depression rating scales) in DM1 is a combination of
physical symptoms of their disease and any emotional/affective
features that are not part of a true mood disorder. These
symptoms are instead the manifestation of the stress involved in
dealing with a chronic and debilitating neurological condition.
Our findings also highlight the concept that these affective
symptoms associated with a chronic disease are heightened in
those with a cognitive disorder as lower FSIQ was associated with
higher depression and anxiety ratings. It has also been shown
that increased cognitive impairment is significantly correlated
with higher BDI-II scores (71). It is likely that DM1 patients
with cognitive deficits are using more emotion-focused coping
strategies instead of problem-focused coping strategies (73). In
summary, we conclude that depression (or anxiety) is not a core
feature of DM1 (27, 74).
Apathy, a disorder of diminished motivation, has long been
associated with DM1, with a prevalence of 40–55% (42). Apathy
has been associated with impairments in social, occupational, and
functional domains including impairments in activities of daily
living, diminished quality of life, increased caregiver burden,
and treatment non-adherence (17). An interesting core feature
of apathy is that it is often not bothersome to the patient
and sometimes not even acknowledged as problematic (lack
of insight). In contrast, family members may express extreme
frustration with their loved-one’s apathy. Although in our sample,
there was wide variance in agreement between a patient’s self-
rated apathy score and the informant-rated apathy score (ranging
from the patient scoring 20 points greater than the informant
to the informant scoring 23 points greater than the patient), it
was the informant ratings that had the strongest relationship
with brain FA with a larger effect size. This suggests that the
informant-rated scores may be a more accurate and consistent
indicator of brain pathology. Additionally, Guercio et al. (75)
found that self-reported apathy scores in Alzheimer’s disease are
less reliable if the subjects have cognitive impairment.
Finally, daytime sleepiness or hypersomnolence is a core
feature of DM1 brain pathology with the current findings
showing strong relationships to low FA. Previous studies have
also shown significant relationships between brain pathology
and neuroimaging findings with sleep problems, including
ventricular enlargement, gray and white matter atrophy,
white matter lesions, decreased volume of the pallidum and
diencephalon, hypoechogenic raphe, iron accumulation in the
caudate nucleus, and decreased neurofibrillary tangles (6, 22,
26, 76, 77). Moreover, white matter tract mean diffusivity in
the superior longitudinal fasciculus and cingulum has been
associated with an increased score on the Epworth Sleepiness
Scale (4). The prevalent symptom of hypersomnolence causes
major morbidity in DM1 (16, 45, 78–81). Although relatively
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FIGURE 1 | Disease duration as a predictor of clinical measures in DM1. Disease duration was not associated with changes in (A) FSIQ (P = 0.085), (B) depression
(P = 0.271), or (C) anxiety (P = 0.508), but was significantly associated with increased scores for the core symptoms of (D) self-reported apathy (P = 0.023), (E)
informant reported-apathy (P < 0.0001), and (F) hypersomnolence (P = 0.0008). Light-blue shaded region represents 95% confidence interval.
crudely tracked by self-report in this current study, this feature
can also be evaluated by quantitative assessment such as EEG
from polysomnography, which could be used in future studies or
clinical trials (82).
A limitation of this present study is a relatively low median
CTG repeat length of 146 and mild MIRS score compared to
other studies, suggesting that the DM1 group is only mildly
affected. However, our study was primarily focused on adult-
onset DM1, and by excluding congenital, childhood, and juvenile
forms of DM1 the median CTG repeat length of 146 was not
unexpected. This could lead to problems generalizing these
results to a larger DM1 population that included congenital,
childhood, and juvenile DM1 patients. Likemost human research
studies, adult-onset DM1 participants that are moderately to
severely affected face greater barriers with research study
participation, thus biasing the study population itself to those
less affected by disease. Another limitation to this study is the
use of self-report questionnaires for measurement of depression,
anxiety, apathy, and hypersomnolence. This could have led to
biased results through misreporting of symptoms.
The current findings highlight the concept that core
features of the disease that are directly related to measures
of brain pathology (lower WM FA) are FSIQ, apathy, and
hypersomnolence. Additionally, as a measure of disease
progression, disease duration was significantly associated with
the core features of apathy, hypersomnolence, and cerebral FA.
Identifying features that represent the true manifestation of brain
pathology in DM1 is of particular importance given that drug
companies are interested in targeting the CNS for clinical trials
of gene knock-down and other therapies. It is important to note
that a correlation to disease duration is only a proxy to disease
progression. Moreover, given the wide range of disease duration
in our sample, it will be possible to evaluate disease progression
in the future. Whether progression in these symptoms occur
rapidly is important to assess in the context of whether or not
they may represent appropriate end-points for clinical trials.
Our study is designed as a prospective longitudinal study and
evaluation of change over a one- and two-year time period is
currently underway.
CONCLUSIONS
Our study supports the hypothesis that the underlying
neuropathology of adult-onset myotonic dystrophy type 1,
as measured by cerebral WM FA and disease duration, leads
directly to cognitive deficits, apathy, and hypersomnolence,
while increased symptoms of depression and anxiety are
secondary to a combination of the physical symptoms of having
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a neuromuscular disorder and the emotional stress of coping
with a chronic and debilitating disorder.
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